← Browse by Condition

Medical Condition

mild cognitive impairment

Total Trials

28

Recruiting Now

28

Trial Phases

Phase 2, Phase 1, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for mild cognitive impairment sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — mild cognitive impairment Clinical Trials

How many clinical trials are currently recruiting for mild cognitive impairment?

ClinicalMetric currently tracks 28 actively recruiting clinical trials for mild cognitive impairment, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 28. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for mild cognitive impairment?

mild cognitive impairment research spans Phase 1 (5 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a mild cognitive impairment clinical trial?

Eligibility criteria for mild cognitive impairment trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

5

Phase 2

2

Top Sponsors

University of Cambridge 2 trials

Johns Hopkins University 2 trials

National Institute of Mental Health (NIMH) 2 trials

Duke University 2 trials

University of California, Davis 1 trial

Recruiting Clinical Trials

The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions

University of Cambridge

NCT04804241 Phase 2

Senicapoc in Alzheimer's Disease

University of California, Davi...

NCT05591027 Phase 1

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Oregon Health and Science Univ...

Voice Technology-Based Self-Management Intervention

Emory University

Comparison of the Effects of Bimanual, Finger and VR Exercises in PwMCI

Eastern Mediterranean Universi...

NCT06005038 Phase 1

CogT pSOPT Intervention Study

Stanford University

MCI Speech in Noise

Dartmouth-Hitchcock Medical Ce...

Improve New Learning and Memory in Individuals With Mild Cognitive Impairment

Kessler Foundation

Prediction of Cognitive Test Performance Using AI-Based Analysis of Narrative Speech

Chang Gung Memorial Hospital

EVASION: Effect of VisuAl Stimulation on attentION

University Hospital, Angers

NCT04123314 EARLY_Phase 1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Johns Hopkins University

NCT07012993 Phase 2

Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol

NCT04396873 Phase 1

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

National Institute of Mental H...

ADRC Clinical Cohort (Alzheimer's Disease)

Duke University

WHIte MAtter Hyperintensity Shape and Glymphatics

Leiden University Medical Cent...

The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia

University of Alabama at Birmi...

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

Columbia University

NCT07169630 Phase 1

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

National Institute of Mental H...

Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease

Helen M. Bronte-Stewart

HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population

Optical Neuroimaging and Cognition

University of Cambridge

Retinal Imaging in Neurodegenerative Disease

Duke University

Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression

IRCCS San Raffaele

CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial

National University Hospital, ...

Choose Myself (Before) Losing Myself

The Cleveland Clinic

Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease

Massachusetts General Hospital

Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment

University of Maryland, Baltim...

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

Johns Hopkins University

Related Conditions

alzheimer disease (9) dementia (7) alzheimer s disease (6) parkinson s disease (4) subjective cognitive decline (3) dementia diagnosis (2) dementia alzheimers (2) dementia mixed (2) dementia vascular (2) cognitive impairment (2) parkinson disease disorder (1) parkinson (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology